Consultation - Proposal regarding the scheduling of 2C-phenethylamines under the Controlled Drugs and Substances Act and its regulations

Notice to the reader:

The Order and Regulations regarding the scheduling of 2C-phenethylamines under the Controlled Drugs and Substances Act have been finalized.  They were published in Canada Gazette, Part II on May 4, 2016. Go to the Canada Gazette (Order) and (Regulations) for further details.

The purpose of this Notice of Consultation is to provide an opportunity to comment on Health Canada's proposal to add 2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers to Schedule III to the Controlled Drugs and Substances Act (CDSA) and to the Schedule to Part J of the Food and Drug Regulations.

In March 2015, the United Nations Commission on Narcotic Drugs voted in favour of scheduling three 2C-phenethylamines derivatives, 25B-NBOMe, 25C-NBOMe, and 25I-NBOMe under Schedule I to the United Nations Convention on Psychotropic Substances, 1971 (1971 Convention). As a signatory, Canada has an obligation to impose controls on these substances and their salts. Given that there are many substances related to these three that also have psychoactive effects, Health Canada is seeking input to determine whether scheduling the entire 2C-phenethylamines class is warranted.

2C-phenethylamines are potent synthetic drugs having both stimulant and hallucinogenic properties. The majority of the risks to the health and safety of Canadians from 2C-phenethylamines are associated with recreational exposures causing unknown toxicological short- and long-term effects that may cause bodily harm, injury, illness or death.

How to Get Involved

Proposed amendments are outlined in a Notice to Interested Parties (NTIP).  The NTIP was published in the Canada Gazette, Part I, on August 1, 2015, initiating a 30-day comment period ending on August 30, 2015.

Go to the  Canada Gazette for further details.

If you are interested in this process or have comments on the proposed changes, please contact:

By mail at:

Regulatory Policy Division,
Controlled Substances and Tobacco Directorate,
Healthy Environments and Consumer Safety Branch,
Health Canada,
Address Locator: 0302A,
Ottawa, Ontario, K1A 0K9.

Page details

Date modified: